Eye Cell Implants Improve Parkinson's Symptoms 
 By Serena Gordon, HealthDay Reporter
 
 MONDAY, April 28 (HealthDay News) -- By implanting specialized cells 
 found in the human eye into areas of the brain damaged by Parkinson's 
 disease, researchers were able to reduce symptoms and improve quality 
 of life in people with moderate to severe Parkinson's.
 
 The new treatment, dubbed Spheramine, reduced symptoms experienced 
 when people were off their Parkinson's medications by 44 percent for 
 as long as four years of follow-up. Quality-of-life measurements were 
 up about 23 percent, according to the study, expected to be presented 
 April 29 at the American Association of Neurological Surgeons' annual 
 meeting, in Chicago.
 
 "This is a promising study on a form of therapy that is different 
 from anything out there," said the study's lead author, Dr. Roy 
 Bakay, a professor of neurological surgery and the A. Watson and 
 Sarah Armour Presidential Chair at Rush University Medical Center in 
 Chicago. 
 
 "This therapy may be beneficial in itself, or it may be used as 
 additional therapy," added Bakay, who was at Emory University in 
 Atlanta at the time of the study. 
 
 Spheramine is made from cells called human retinal pigment epithelial 
 cells (hRPE) that are found naturally in the human eye. By combining 
 these cells with microscopic gelatin beads called microcarrier 
 support matrix (MSM), the Emory researchers were able to produce 
 Spheramine, a targeted therapy for Parkinson's. Spheramine can be 
 implanted in the brain, where the eye cells naturally begin to 
 produce levodopa. The researchers believe the levodopa is then turned 
 into dopamine, a neurotransmitter lacking in people with Parkinson's. 
 
 "Spheramine is not stem cells. There's no requirement for 
 immunosuppression, and these cells are easily harvested from eye 
 banks and are readily available," Bakay said.
 
 The new study included six patients with moderate to severe 
 Parkinson's disease, a progressive brain disorder that causes tremors 
 and other motor difficulties that worsen as the disease advances. 
 Parkinson's affects as many 1.5 million Americans, according to 
 background information in the study.
 
 There are few effective treatments for Parkinson's, and those that do 
 work often have unpleasant side effects and may stop working over 
 time.
 
 Patients selected for the study were chosen based on their 
 responsiveness to levodopa and the severity of their symptoms when 
 they were off their medication. Using MRI-guided stereotactic 
 surgery, the researchers implanted Spheramine into areas of the 
 volunteers' brains that appeared to be most affected by Parkinson's. 
 
 After 12 months, there was a 48 percent improvement in symptoms. At 
 48 months, that number had dropped to 44 percent, but Bakay said the 
 researchers were pleased that the treatment maintained effectiveness 
 for that long. 
 
 The only significant side effect seen in this small study was a 
 transient headache, he said. 
 
 Dr. Bruce Silverman, a neurologist at Providence Hospital and Medical 
 Center in Southfield, Mich., said the new study "showed that there 
 was clinical improvement over a sustained period of time. The study 
 was based on small numbers, but it shows some promise." 
 
 He added that the study needs to replicated with a larger group of 
 patients. 
 
 Bakay said the researchers have recently completed a larger, double-
 blind study, and results of that trial should be available by the end 
 of this year or early 2009. 
 
 More information
 
 To learn more about treatments available for Parkinson's disease, 
 visit the National Parkinson Foundation.
 
 SOURCES: Roy Bakay, M.D., professor, neurological surgery, and the A. 
 Watson and Sarah Armour Presidential Chair, Rush University Medical 
 Center, Chicago; Bruce Silverman, D.O., neurologist, Providence 
 Hospital and Medical Center, Southfield, Mich.; April 29, 2008, 
 presentation, American Association of Neurological Surgeons' annual 
 meeting, Chicago
 http://www.wtnzfox4
 
 
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___




